Welcome to LookChem.com Sign In|Join Free
  • or
(S)-methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

156335-14-7

Post Buying Request

156335-14-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

156335-14-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 156335-14-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,3,3 and 5 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 156335-14:
(8*1)+(7*5)+(6*6)+(5*3)+(4*3)+(3*5)+(2*1)+(1*4)=127
127 % 10 = 7
So 156335-14-7 is a valid CAS Registry Number.

156335-14-7Relevant academic research and scientific papers

An asymmetric synthesis of PPAR-γ agonist navaglitazar from (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate

Rizzo, John R.,Zhang, Tony Y.

, p. 580 - 583 (2007/10/03)

An asymmetric synthesis of navaglitazar, a peroxisome proliferator activated receptor (PPAR) γ agonist, from commercially available (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate, is described. The new synthesis features high overall yield, low solvent usage, crystalline intermediates and operational simplicity. Schweizerische Chemische Gesellschaft.

PROCESS FOR THE PRODUCTION OF ALPHA-ALKOXY/HYDROXY-BETA-(P-HYDROXYPHENYL) PROPIONIC ACID DERIVATIVES

-

Page/Page column 9, (2010/02/11)

The present invention describes the production of compounds having the general formula (I) starting from compounds having the general formula (II) and (III) The products are intermediates for the production of bioactive substances.

SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS

-

Page/Page column 31-32, (2010/02/12)

The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disor

2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents

Martín, José A.,Brooks, Dawn A.,Prieto, Lourdes,González, Rosario,Torrado, Alicia,Rojo, Isabel,López De Uralde, Beatriz,Lamas, Carlos,Ferritto, Rafael,Dolores Martín-Ortega, María,Agejas, Javier,Parra, Francisco,Rizzo, John R.,Rhodes, Gary A.,Robey, Roger L.,Alt, Charles A.,Wendel, Samuel R.,Zhang, Tony Y.,Reifel-Miller, Anne,Montrose-Rafizadeh, Chahrzad,Brozinick, Joseph T.,Hawkins, Eric,Misener, Elizabeth A.,Briere, Daniel A.,Ardecky, Robert,Fraser, James D.,Warshawsky, Alan M.

, p. 51 - 55 (2007/10/03)

Herein we describe a series of potent and selective PPARγ agonists with moderate PPARα affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes. Herein we describe a series of potent and selective PPARγ agonists with moderate PPARα affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes.

AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS

-

Page 26, (2010/02/05)

The present invention is directed to compounds, compositions, and use of compounds the structural Formula (I).

Heterocyclic compounds as pharmaceutical

-

, (2008/06/13)

Compounds of Formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein A1, A2, A3, R2, X, Y and n are as define

Non thiazolidinedione antihyperglycaemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids

Buckle,Cantello,Cawthorne,Coyle,Dean,Faller,Haigh,Hindley,Jefcott,Lister,Pinto,Rami,Smith,Smith

, p. 2121 - 2126 (2007/10/03)

The 5-benzylthiazolidine-2,4-dione moiety of insulin sensitising antidiabetic agents can be replaced by a range of α-heteroatom functionalised β-phenylpropanoic acids. α-Oxy-carboxylic acids show potent antidiabetic activity and one compound, the α-ethoxyacid 15 (SB 213068), is one of the most potent antihyperglycaemic agents yet reported.

Competing O - H insertion and β-elimination in rhodium carbenoid reactions; synthesis of 2-alkoxy-3-arylpropanoates

Cox, Geoffrey G.,Haigh, David,Hindley, Richard M.,Miller, David J.,Moody, Christopher J.

, p. 3139 - 3142 (2007/10/02)

Rhodium(II) carboxylate catalysed decomposition of diazo esters 3 and 4 in the presence of alcohols or water results in formation of 2-alkoxy- or 2-hydroxy-3-arylpropanoates respectively by O - H insertion in competition with cinnamates by elimination; the ratio of insertion to elimination is dramatically affected by the carboxylate ligand on rhodium. Use of methanol-d as the alcohol confirms that the alkene does not arise by elimination from the initial alkoxyester product.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 156335-14-7